A review of the diagnosis and management of male breast cancer

Oncologist

Volumn 10, Issue 7, 2005, Pages 471-479

  Giordano, Sharon H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Epidemiology; Male breast cancer; Prognosis

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTIANDROGEN; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; FULVESTRANT; GESTAGEN; GONADORELIN AGONIST; LETROZOLE; STEROID; TAMOXIFEN; TRASTUZUMAB;

ALGORITHM; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; FAMILY HISTORY; GENE MUTATION; GYNECOMASTIA; HUMAN; LYMPH NODE DISSECTION; MALE; MALE BREAST; MAMMOGRAPHY; MASTECTOMY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENTINEL LYMPH NODE; TREATMENT OUTCOME;

BREAST NEOPLASMS, MALE; HUMANS; MALE; RISK FACTORS; SURVIVAL RATE;

EID: 24644432489     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-7-471     Document Type: Review

References (95)

1. Bagley CS, Wesley MN, Young RC et al. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987;10:55-60.
2. Giordano SH, Cohen DS, Buzdar AU et al. Breast carcinoma in men: a population-based study. Cancer 2004;101:51-57.
3. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
4. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
5. Crichlow RW. Carcinoma of the male breast. Surg Gynecol Obstet 1972;134:1011-1019.
6. Ewertz M, Holmberg L, Karjalainen S et al. Incidence of male breast can-cer in Scandinavia, 1943-1982. Int J Cancer 1989;43:27-31.
7. Surveillance, Epidemiology, and End Results Program. Available at http://www.seer.cancer.gov. Accessed August 16, 2004.
8. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993;53:538-549.
9. Thomas DB, Jimenez LM, McTiernan A et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol 1992;135:734-748.
10. Goss PE, Reid C, Pintilie M et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999;85:629-639.
11. Yildirim E, Berberoglu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol 1998;24:548-552.
12. Braunstein GD. Gynecomastia. N Engl J Med 1993;328:490-495.
13. Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter's syndrome. J Med Genet 1971;8:460-461.
14. Hultborn R, Hanson C, Kopf I et al. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 1997;17:4293-4297.
15. Casagrande JT, Hanisch R, Pike MC et al. A case-control study of male breast cancer. Cancer Res 1988;48:1326-1330.
16. Rosenblatt KA, Thomas DB, McTiernan A et al. Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst 1991;83:849-854.
17. Sorensen HT, Friis S, Olsen JH et al. Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol 1998;93:231-233.
18. Weiderpass E, Ye W, Adami HO et al. Breast cancer risk in male alcoholics in Sweden. Cancer Causes Control 2001;12:661-664.
19. Hsing AW, McLaughlin JK, Cocco P et al. Risk factors for male breast cancer (United States). Cancer Causes Control 1998;9:269-275.
20. Johnson KC, Pan S, Mao Y. Risk factors for male breast cancer in Canada, 1994-1998. Eur J Cancer Prev 2002;11:253-263.
21. Ewertz M, Holmberg L, Tretli S et al. Risk factors for male breast cancer - a case-control study from Scandinavia. Acta Oncol 2001;40:467-471.
22. Rosenblatt KA, Thomas DB, Jimenez LM et al. The relationship between diet and breast cancer in men (United States). Cancer Causes Control 1999;10:107-113.
23. Pollan M, Gustavsson P, Floderus B. Breast cancer, occupation, and exposure to electromagnetic fields among Swedish men. Am J Ind Med 2001;39:276-285.
24. Erren TC. A meta-analysis of epidemiologic studies of electric and magnetic fields and breast cancer in women and men. Bioelectromagnetics 2001;(suppl 5):S105-S119.
25. Sverdlov RS, Barshack I, Bar Sade RB et al. Genetic analyses of male breast cancer in Israel. Genet Test 2000;4:313-317.
26. Struewing JP, Brody LC, Erdos MR et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995;57:1-7.
27. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-689.
28. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490.
29. Basham VM, Lipscombe JM, Ward JM et al. BRCA1 and BRCA2 mutations in apopulation-based study of male breast cancer. Breast Cancer Res 2002;4:R2.
30. Ottini L, Masala G, D'Amico C et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 2003;63:342-347.
31. Friedman LS, Gayther SA, Kurosaki T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60:313-319.
32. Thorlacius S, Olafsdottir G, Tryggvadottir L et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13:117-119.
33. Kwiatkowska E, Teresiak M, Filas V et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res 2003;9:4452-4459.
34. Wooster R, Mangion J, Eeles R et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992;2:132-134.
35. Lobaccaro JM, Lumbroso S, Belon C et al. Androgen receptor gene mutation in male breast cancer. Hum Mol Genet 1993;2:1799-1802.
36. Syrjakoski K, Hyytinen ER, Kuukasjarvi T et al. Androgen receptor gene alterations in Finnish male breast cancer. Breast Cancer Res Treat 2003;77:167-170.
37. Fackenthal JD, Marsh DJ, Richardson AL et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001;38:159-164.
38. Boyd J, Rhei E, Federici MG et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 1999;53:87-91.
39. Stalsberg H, Thomas DB, Rosenblatt KA et al. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control 1993;4:143-151.
40. Hittmair AP, Lininger RA, Tavassoli FA. Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma-a preliminary report. Cancer 1998;83:2139-2149.
41. Sanchez AG, Villanueva AG, Redondo C. Lobular carcinoma of the breast in a patient with Klinefelter's syndrome. A case with bilateral, synchronous, histologically different breast tumors. Cancer 1986;57:1181-1183.
42. Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol 1992;5:621-625.
43. Wick MR, Sayadi H, Ritter JH et al. Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol 1999;111:59-69.
44. Willsher PC, Leach IH, Ellis IO et al. Male breast cancer: pathological and immunohistochemical features. Anticancer Res 1997;17:2335-2338.
45. Bloom KJ, Govil H, Gattuso P et al. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001;182:389-392.
46. Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med 2003;127:36-41.
47. Blin N, Kardas I, Welter C et al. Expression of the c-erbB2 proto-oncogene in male breast carcinoma: lack of prognostic significance. Oncology 1993;50:408-411.
48. Leach IH, Ellis IO, Elston CW. c-erb-B-2 expression in male breast carcinoma. J Clin Pathol 1992;45:942.
49. Rayson D, Erlichman C, Suman VJ et al. Molecular markers in male breast carcinoma. Cancer 1998;83:1947-1955.
50. Pich A, Margaria E, Chiusa L et al. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association. Br J Cancer 1999;79:959-964.
51. Kidwai N, Gong Y, Sun X et al. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res 2004;6: R18-R23.
52. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678-687.
53. Stierer M, Rosen H, Weitensfelder W et al. Male breast cancer: Austrian experience. World J Surg 1995;19:687-692; discussion 692-693.
54. Scott-Conner CE, Jochimsen PR, Menck HR et al. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 1999;126:775-780; discussion 780-781.
55. Williams MJ. Gynecomastia. Its incidence, recognition and host characterization in 447 autopsy cases. Am J Med 1963;34:103-112.
56. Evans GF, Anthony T, Turnage RH et al. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg 2001;181:96-100.
57. Gunhan-Bilgen I, Bozkaya H, Ustun EE et al. Male breast disease: clinical, mammographic, and ultrasonographic features. Eur J Radiol 2002;43:246-255.
58. Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-3636.
59. Guinee VF, Olsson H, Moller T et al. The prognosis of breast cancer in males. A report of 335 cases. Cancer 1993;71:154-161.
60. Ribeiro G, Swindell R, Harris M et al. A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast 1996;5:141-146.
61. Scheike O. Male breast cancer. 6. Factors influencing prognosis. Br J Cancer 1974;30:261-271.
62. Donegan WL, Redlich PN, Lang PJ et al. Carcinoma of the breast in males: a multiinstitutional survey. Cancer 1998;83:498-509.
63. Ouriel K, Lotze MT, Hinshaw JR. Prognostic factors of carcinoma of the male breast. Surg Gynecol Obstet 1984;159:373-376.
64. Gough DB, Donohue JH, Evans MM et al. A 50-year experience of male breast cancer: is outcome changing? Surg Oncol 1993;2:325-333.
65. Turner L, Swindell R, Bell WG et al. Radical versus modified radical mastectomy for breast cancer. Ann R Coll Surg Engl 1981;63:239-243.
66. Maddox WA, Carpenter JT Jr, Laws HL et al. A randomized prospective trial of radical (Halsted) mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg 1983;198:207-212.
67. Cutuli B, Lacroze M, Dilhuydy JM et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995;31A:1960-1964.
68. Albo D, Ames FC, Hunt KK et al. Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy. Breast Cancer Res Treat 2003;77:9-14.
69. Cimmino VM, Degnim AC, Sabel MS et al. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol 2004;86:74-77.
70. Goyal A, Horgan K, Kissin M et al. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol 2004;30:480-483.
71. Port ER, Fey JV, Cody HS 3rd et al. Sentinel lymph node biopsy in patients with male breast carcinoma. Cancer 2001;91:319-323.
72. De Cicco C, Baio SM, Veronesi P et al. Sentinel node biopsy in male breast cancer. Nucl Med Commun 2004;25:139-143.
73. Spence RA, MacKenzie G, Anderson JR et al. Long-term survival following cancer of the male breast in Northern Ireland. A report of 81 cases. Cancer 1985;55:648-652.
74. Erlichman C, Murphy KC, Elhakim T. Male breast cancer: a 13-year review of 89 patients. J Clin Oncol 1984;2:903-909.
75. Perkins GH, Middleton LP, Garcia SM et al. Male breast carcinoma: outcomes and predictors of local-regional failure in patients treated without radiation therapy. Breast Cancer Res Treat 2002;76:121.
76. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-942.
77. Patel HZ 2nd, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 1989;64:1583-1585.
78. Izquierdo M A, Alonso C, De Andres L et al. Male breast cancer. Report of a series of 50 cases. Acta Oncol 1994;33:767-771.
79. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992;65:252-254.
80. Giordano SH, Perkins G, Garcia SM et al. Male breast cancer: the M. D. Andersen experience with adjuvant therapy. Breast Cancer Res Treat 2003;82:S42.
81. Anelli TF, Anelli A, Tran KN et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994;74:74-77.
82. Giordano SH, Valero V, Buzdar AU et al. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25:235-237.
83. Mauras N, O'Brien KO, Klein KO et al. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000;85:2370-2377.
84. Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 2005;90:26-30.
85. Italiano A, Largillier R, Marcy PY et al. [Complete remission obtained with letrozole in a man with metastatic breast cancer]. Rev Med Interne 2004;25:323-324. French.
86. Farrow J, Adair F. Effect of Orchiectomy on skeletal metastases from cancer of the male breast. Science 1942;95:654.
87. Jaiyesimi IA, Buzdar AU, Sahin AA et al. Carcinoma of the male breast. Ann Intern Med 1992;117:771-777.
88. Labrie F, Dupont A, Belanger A et al. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. Clin Invest Med 1990;13:275-278.
89. Lopez M, Natali M, Di Lauro L et al. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer 1993;72:502-505.
90. Doberauer C, Niederle N, Schmidt CG. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 1988;62:474-478.
91. Dong C, Hemminki K. Second primary breast cancer in men. Breast Cancer Res Treat 2001;66:171-172.
92. Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 2002;94:1330-1332.
93. Couch FJ, Farid LM, DeShano ML et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13:123-125.
94. Haraldsson K, Loman N, Zhang QX et al. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998;58:1367-1371.
95. Kwiatkowska E, Teresiak M, Lamperska KM et al. BRCA2 germline mutations in male breast cancer patients in the Polish population. Hum Mutat 2001;17:73.